Walvax Biotechnology Co., Ltd. (SHE:300142)

Market Cap	19.35B
Revenue (ttm)	2.40B
Net Income (ttm)	49.24M
Shares Out	1.60B
EPS (ttm)	0.03
PE Ratio	392.98
Forward PE	55.63
Dividend	0.01 (0.08%)
Ex-Dividend Date	May 28, 2025

Volume	43,876,446
Average Volume	45,883,850
Open	12.75
Previous Close	12.54
Day's Range	12.05 - 12.75
52-Week Range	9.70 - 15.57
Beta	0.45
RSI	47.45
Earnings Date	Oct 29, 2025

About Walvax Biotechnology

Walvax Biotechnology Co., Ltd., engages in the research and development, manufacture, and distribution of vaccines in China. Its vaccine portfolio includes recombinant human papillomavirus bivalent, 13-valent pneumococcal polysaccharide conjugate, 23-valent pneumococcal polysaccharide, group ACYW135 meningococcal polysaccharide, group A and C meningococcal polysaccharide, group A and group C meningococcal conjugate, and haemophilus influenzae type b conjugate vaccines, as well as diphtheria, tetanus and acellular pertussis combined vaccine. The...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2001
• Employees: 2,388
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300142

Financial Performance

In 2024, Walvax Biotechnology's revenue was 2.82 billion, a decrease of -31.41% compared to the previous year's 4.11 billion. Earnings were 142.16 million, a decrease of -66.10%.